Literature DB >> 9466782

Multicenter evaluation of the new automated Enzymun-Test Anti-HIV 1 + 2 + subtyp O.

B Weber1.   

Abstract

An international multicenter study was performed to evaluate a new, automated human immunodeficiency virus (HIV) third-generation antibody assay. The Enzymun-Test Anti-HIV 1 + 2 + Subtyp O showed 100% sensitivity and 99.8% specificity among 11,172 samples from hospitalized patients and blood donors. For early HIV antibody detection in seroconversion panels, Enzymun-Test showed a sensitivity equivalent to that of the Abbott Recomb. HIV-1/HIV-2 3rd Gen. assay.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9466782      PMCID： PMC104583     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Acidification modified p24 antigen capture assay in HIV seropositives.

Authors:  D P Ascher; C Roberts; A Fowler
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1992

2.  Acquired immunodeficiency syndrome (AIDS). Proposed WHO criteria for interpreting results from western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  1990-09-14

3.  Multicenter evaluation of the novel ABN Western blot (immunoblot) system in comparison with an enzyme-linked immunosorbent assay and a different Western blot.

Authors:  B Weber; G Hess; R Enzensberger; F Harms; C J Evans; A Hamann; H W Doerr
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

4.  Detection of human immunodeficiency virus type 1 and type 2 antibodies by a new automated microparticle immunoassay AxSYM HIV-1/HIV-2.

Authors:  B Weber; N Behrens; H W Doerr
Journal:  J Virol Methods       Date:  1997-01       Impact factor: 2.014

5.  Interpretation and use of the western blot assay for serodiagnosis of human immunodeficiency virus type 1 infections.

Authors: 
Journal:  MMWR Suppl       Date:  1989-07-21

6.  Serologic tests for the retroviruses: approaching a decade of evolution.

Authors:  N T Constantine
Journal:  AIDS       Date:  1993-01       Impact factor: 4.177

7.  A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon.

Authors:  L G Gürtler; P H Hauser; J Eberle; A von Brunn; S Knapp; L Zekeng; J M Tsague; L Kaptue
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  Early detection of antibodies to HIV-1 by third-generation assays.

Authors:  H L Zaaijer; P v Exel-Oehlers; T Kraaijeveld; E Altena; P N Lelie
Journal:  Lancet       Date:  1992-09-26       Impact factor: 79.321

9.  Thirteen current anti-HIV-1/HIV-2 enzyme immunoassays: how accurate are they?

Authors:  L McAlpine; J Gandhi; J V Parry; P P Mortimer
Journal:  J Med Virol       Date:  1994-02       Impact factor: 2.327

10.  Evaluation of the automated 'Enzymen-Test Anti HIV-1 + 2' and 'Enzymen-Test Anti HIV-1/2 selective' for the combined detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies.

Authors:  B Weber; G Hess; R Koberstein; H W Doerr
Journal:  J Virol Methods       Date:  1993-10       Impact factor: 2.014
View more
  5 in total

1.  Evaluation of the Bio-Rad Geenius HIV 1/2 assay as an alternative to the INNO-LIA HIV 1/2 assay for confirmation of HIV infection.

Authors:  Orna Mor; Fernando Mileguir; Michal Michaeli; Itzchak Levy; Ella Mendelson
Journal:  J Clin Microbiol       Date:  2014-04-30       Impact factor: 5.948

2.  Multiple routes of drug administration and HIV risk among injecting drug users.

Authors:  Sigrid Vorobjov; Anneli Uusküla; Don C Des Jarlais; Katri Abel-Ollo; Ave Talu; Kristi Rüütel
Journal:  J Subst Abuse Treat       Date:  2011-11-23

3.  Socio-demographic factors, health risks and harms associated with early initiation of injection among people who inject drugs in Tallinn, Estonia: evidence from cross-sectional surveys.

Authors:  Sigrid Vorobjov; Don C Des Jarlais; Katri Abel-Ollo; Ave Talu; Kristi Rüütel; Anneli Uusküla
Journal:  Int J Drug Policy       Date:  2012-10-01

4.  Early identification of seronegative human immunodeficiency virus type 1 infection with severe presentation.

Authors:  Bum Sik Chin; Sun Hee Lee; Gab Jung Kim; Mee Kyung Kee; Soon Deok Suh; Sung Soon Kim
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

5.  Comparison of injecting drug users who obtain syringes from pharmacies and syringe exchange programs in Tallinn, Estonia.

Authors:  Sigrid Vorobjov; Anneli Uusküla; Katri Abel-Ollo; Ave Talu; Kristi Rüütel; Don C Des Jarlais
Journal:  Harm Reduct J       Date:  2009-02-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.